AmirAli Talasaz
Research Subjects
Research Interests
AmirAli Talasaz has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Victoria M. Raymond
Guardant Health Inc, Redwood City, CA
12 shared publications - Chloe E. Atreya
Helen Diller Family Comprehensive Cancer Center 1 San Francisco, California
11 shared publications - Oliver A. Zill
Genentech, South San Francisco, USA
11 shared publications - Andrew H. Ko
University of California San Francisco, San Francisco, CA
10 shared publications - Andrew Hendifar
Cedars-Sinai Medical Center, Los Angeles, CA 90211, USA
10 shared publications Claire Greene
10 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (5) , 671-677
Cost-effectiveness of blood-based colorectal cancer screening – a simulation model incorporating real-world longitudinal adherence
Although U.S. Preventive Services Task Force (USPSTF) recommended CRC screenings are effective; patient reluctance reduces adherence. Most cost-effectiveness models assume perfect adherence, yet one-third of eligible individuals aren't current with CRC screening. Our study assesses the cost-effectiveness of Shield, an FDA-approved blood-based CRC screening test, using real-world adherence. The CAN-SCREEN (Colorectal cANcer SCReening Economics and adherENce) model, a validated discrete-event simulation, evaluated clinical and economic outcomes of CRC screening under real-world adherence scenarios. We compared the Shield blood-based test administered every 3 years to no screening, considering it cost-effective if the incremental cost-effectiveness ratio (ICER) was under $100,000 per quality-adjusted life-year (QALY) gained. Shield increased QALYs by 154 and raised costs by $7.5 million per 1,000 individuals, with an ICER of $48,662 per QALY, meeting the $100,000/QALY threshold. Shield remained cost-effective up to a unit cost of $3,241 (at $100,000/QALY) and $4,942 (at $150,000/QALY). Sensitivity analyses confirmed cost-effectiveness with lower adherence to diagnostic colonoscopy (56.1%) and annual screenings. The CAN-SCREEN model shows that Shield is cost-effective compared to no screening. Including real-world adherence improves accuracy in assessing screening strategies. Shield's noninvasive approach offers a promising, cost-effective way to increase adherence and reduce CRC mortality.
- 3 February 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 25 (5) , 671-677
Open AccessCost-effectiveness of blood-based colorectal cancer screening – a simulation model incorporating real-world longitudinal adherence
Although U.S. Preventive Services Task Force (USPSTF) recommended CRC screenings are effective; patient reluctance reduces adherence. Most cost-effectiveness models assume perfect adherence, yet one-third of eligible individuals aren't current with CRC screening. Our study assesses the cost-effectiveness of Shield, an FDA-approved blood-based CRC screening test, using real-world adherence. The CAN-SCREEN (Colorectal cANcer SCReening Economics and adherENce) model, a validated discrete-event simulation, evaluated clinical and economic outcomes of CRC screening under real-world adherence scenarios. We compared the Shield blood-based test administered every 3 years to no screening, considering it cost-effective if the incremental cost-effectiveness ratio (ICER) was under $100,000 per quality-adjusted life-year (QALY) gained. Shield increased QALYs by 154 and raised costs by $7.5 million per 1,000 individuals, with an ICER of $48,662 per QALY, meeting the $100,000/QALY threshold. Shield remained cost-effective up to a unit cost of $3,241 (at $100,000/QALY) and $4,942 (at $150,000/QALY). Sensitivity analyses confirmed cost-effectiveness with lower adherence to diagnostic colonoscopy (56.1%) and annual screenings. The CAN-SCREEN model shows that Shield is cost-effective compared to no screening. Including real-world adherence improves accuracy in assessing screening strategies. Shield's noninvasive approach offers a promising, cost-effective way to increase adherence and reduce CRC mortality.
- Open Access
- 1 August 2024
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 27 (1) , 991-1002
Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence
Insufficient adherence to colorectal cancer (CRC) screening impedes individual and population health benefits, with about one-third of individuals non-adherent to available screening options. The impact of poor adherence is inadequately considered in most health economics models, limiting the evaluation of real-world population-level screening outcomes. This study introduces the CAN-SCREEN (Colorectal cANcer SCReening Economics and adherENce) model, utilizing real-world adherence scenarios to assess the effectiveness of a blood-based test (BBT) compared to existing strategies. The CAN-SCREEN model evaluates various CRC screening strategies per 1,000 screened individuals for ages 45-75. Adherence is modeled in two ways: 1) full adherence and 2) longitudinally declining adherence. BBT performance is based on recent pivotal trial data, while existing strategies are informed using literature. The full adherence model is calibrated using previously published Cancer Intervention and Surveillance Modeling Network (CISNET) models. Outcomes, including life-years gained (LYG), CRC cases averted, CRC deaths averted, and colonoscopies, are compared to no screening. Longitudinal adherence modeling reveals differences in the relative ordering of health outcomes and resource utilization, as measured by the number of colonoscopies performed per 1,000, between screening modalities. BBT outperforms fecal immunochemical test (FIT) and the multitarget stool DNA (mtsDNA) test with more CRC deaths averted (13) compared to FIT and mtsDNA (7, 11), more CRC cases averted (27 vs. 16, 22) and higher LYG (214 vs. 157, 199). BBT yields fewer CRC deaths averted compared to colonoscopy (13, 15) but requires fewer colonoscopies (1,053 vs. 1,928). Due to limited data, the CAN-SCREEN model with longitudinal adherence leverages evidence-informed assumptions for the natural history and real-world longitudinal adherence to screening. The CAN-SCREEN model demonstrates that amongst non-invasive CRC screening strategies, those with higher adherence yield more favorable health outcomes as measured by CRC deaths averted, CRC cases averted, and LYG.
- 1 August 2024
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 27 (1) , 991-1002
Open AccessPopulation health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence
Insufficient adherence to colorectal cancer (CRC) screening impedes individual and population health benefits, with about one-third of individuals non-adherent to available screening options. The impact of poor adherence is inadequately considered in most health economics models, limiting the evaluation of real-world population-level screening outcomes. This study introduces the CAN-SCREEN (Colorectal cANcer SCReening Economics and adherENce) model, utilizing real-world adherence scenarios to assess the effectiveness of a blood-based test (BBT) compared to existing strategies. The CAN-SCREEN model evaluates various CRC screening strategies per 1,000 screened individuals for ages 45-75. Adherence is modeled in two ways: 1) full adherence and 2) longitudinally declining adherence. BBT performance is based on recent pivotal trial data, while existing strategies are informed using literature. The full adherence model is calibrated using previously published Cancer Intervention and Surveillance Modeling Network (CISNET) models. Outcomes, including life-years gained (LYG), CRC cases averted, CRC deaths averted, and colonoscopies, are compared to no screening. Longitudinal adherence modeling reveals differences in the relative ordering of health outcomes and resource utilization, as measured by the number of colonoscopies performed per 1,000, between screening modalities. BBT outperforms fecal immunochemical test (FIT) and the multitarget stool DNA (mtsDNA) test with more CRC deaths averted (13) compared to FIT and mtsDNA (7, 11), more CRC cases averted (27 vs. 16, 22) and higher LYG (214 vs. 157, 199). BBT yields fewer CRC deaths averted compared to colonoscopy (13, 15) but requires fewer colonoscopies (1,053 vs. 1,928). Due to limited data, the CAN-SCREEN model with longitudinal adherence leverages evidence-informed assumptions for the natural history and real-world longitudinal adherence to screening. The CAN-SCREEN model demonstrates that amongst non-invasive CRC screening strategies, those with higher adherence yield more favorable health outcomes as measured by CRC deaths averted, CRC cases averted, and LYG.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 3331
Abstract 3331: Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow
Background. Multi-cancer blood-based tests may yield clinical benefit by improving compliance to guideline recommended screening with a more patient-friendly modality, and also by detection of early (stage I/II) tumors in cancer types that lack screening tests, yet early intervention can save lives. A single test with clinically meaningful performance which addresses both opportunities has yet to be developed. Methods. We evaluated a blood-based multi-modal device based on cfDNA epigenomic and targeted protein analysis that enables high performance for early-stage cancer detection in colon, lung, bladder, gastric, liver, ovarian, and pancreas cancers. Blood samples were obtained from multiple case-control cohorts of individuals with colorectal (N > 2,000), lung (N > 300), and other solid tumor cancers (bladder, gastric, liver, ovarian, pancreas (N > 300)) as well as individuals without cancer (N > 3,000). The assay is based on Guardant Shield™ blood-based CRC screening test and the bioinformatic pipeline is augmented with a multi-cancer screening caller for the detection of additional cancers. Sensitivity for CRC and lung cancer detection is calculated at 90% target specificity thresholds, due to availability of guideline recommended screening tests, colonoscopy and LDCT scan to adjudicate blood-based test results. Specificity for all other cancers were targeted at an overall specificity of 98%. The specificity thresholds for CRC, lung, and multi-cancer are selected to yield assay performance tailored for the cancer type and clinical diagnostic pathway. Results. In this study cohort, this integrated, single device, multi-cancer test yielded CRC sensitivity of 91% (stage I/II: 93%) and lung cancer sensitivity of 85% (stage I/II: 75%) at 90% specificity. The overall sensitivity in bladder, gastric, liver, ovarian, and pancreas cancers was 75% (stage I/II: 66%) at 98% overall specificity. Overall prevalence-adjusted sensitivity of this device in the above 7 cancers were 79% overall sensitivity (stage I/II: 78%). This blood-based test could detect 25% of the expected cancer diagnoses in 2022 according to SEER estimates. Conclusions. This highly-sensitive, integrated, blood-based cancer screening device yields performance on par with currently available screening tests for cancers with screening guidelines (CRC and lung) and clinically meaningful early-stage detection in cancer types without screening guidelines where early intervention can bring clinical benefit, highlighting the ability of this technology to yield clinically meaningful results for the detection of early stage cancer. The performance of this device is under investigation in prospective screening trials. Citation Format: Yupeng He, Anton Valouev, Liyang Xiong, William W. Young Greenwald, Victoria M. Raymond, Sven Duenwald, AmirAli Talasaz. Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3331.
- 4 April 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (7_Suppleme) , 3331
Open AccessAbstract 3331: Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow
Background. Multi-cancer blood-based tests may yield clinical benefit by improving compliance to guideline recommended screening with a more patient-friendly modality, and also by detection of early (stage I/II) tumors in cancer types that lack screening tests, yet early intervention can save lives. A single test with clinically meaningful performance which addresses both opportunities has yet to be developed. Methods. We evaluated a blood-based multi-modal device based on cfDNA epigenomic and targeted protein analysis that enables high performance for early-stage cancer detection in colon, lung, bladder, gastric, liver, ovarian, and pancreas cancers. Blood samples were obtained from multiple case-control cohorts of individuals with colorectal (N > 2,000), lung (N > 300), and other solid tumor cancers (bladder, gastric, liver, ovarian, pancreas (N > 300)) as well as individuals without cancer (N > 3,000). The assay is based on Guardant Shield™ blood-based CRC screening test and the bioinformatic pipeline is augmented with a multi-cancer screening caller for the detection of additional cancers. Sensitivity for CRC and lung cancer detection is calculated at 90% target specificity thresholds, due to availability of guideline recommended screening tests, colonoscopy and LDCT scan to adjudicate blood-based test results. Specificity for all other cancers were targeted at an overall specificity of 98%. The specificity thresholds for CRC, lung, and multi-cancer are selected to yield assay performance tailored for the cancer type and clinical diagnostic pathway. Results. In this study cohort, this integrated, single device, multi-cancer test yielded CRC sensitivity of 91% (stage I/II: 93%) and lung cancer sensitivity of 85% (stage I/II: 75%) at 90% specificity. The overall sensitivity in bladder, gastric, liver, ovarian, and pancreas cancers was 75% (stage I/II: 66%) at 98% overall specificity. Overall prevalence-adjusted sensitivity of this device in the above 7 cancers were 79% overall sensitivity (stage I/II: 78%). This blood-based test could detect 25% of the expected cancer diagnoses in 2022 according to SEER estimates. Conclusions. This highly-sensitive, integrated, blood-based cancer screening device yields performance on par with currently available screening tests for cancers with screening guidelines (CRC and lung) and clinically meaningful early-stage detection in cancer types without screening guidelines where early intervention can bring clinical benefit, highlighting the ability of this technology to yield clinically meaningful results for the detection of early stage cancer. The performance of this device is under investigation in prospective screening trials. Citation Format: Yupeng He, Anton Valouev, Liyang Xiong, William W. Young Greenwald, Victoria M. Raymond, Sven Duenwald, AmirAli Talasaz. Highly sensitive blood-based multi-cancer screening device with tiered specificity based on diagnostic workflow [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3331.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas